Overview

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)

Status:
Not yet recruiting

Trial end date:
2026-09-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of crovalimab compared with placebo as an add-on therapy to intravenous immunoglobulin (IVIg) in participants with severe GBS.

Phase:

Phase 3

Details

Lead Sponsor:

Hoffmann-La Roche

Collaborator:

Chugai Pharmaceutical Co., Ltd. (Sponsor in Taiwan and Japan)

Treatments:

Antibodies
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin